News

FDA upheaval pushes some biotech firms to plan early trials out of US
Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...
Feds recommend pausing vaccine for mosquito-borne disease chikungunya in people over 60
The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...
Stocktwits on MSN1d
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup
Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries ...
BioPharma Dive2d
FDA follows EMA in limiting use of Valneva shot
Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...
MedPage Today1d
FDA/CDC Call Time Out on Ixchiq Vaccine for Older Adults
Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...
BioSpace2d
FDA, EU Flag Safety Issues With Valneva’s Chikungunya Vaccine
The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...
Fierce Pharma2d
FDA, CDC call for pause of chikungunya shot rollout in older adults
On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...
Yahoo Finance7d
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review ...